{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:27:27Z","timestamp":1793611647692,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.arbres.2026.05.015","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:46:55Z","timestamp":1780616815000},"page":"780-788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Longitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease"],"prefix":"10.1016","volume":"62","author":[{"given":"Maxime","family":"Billotte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houda","family":"Camara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Moulinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efs","family":"Bolko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e9vin","family":"Didier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Dury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Devilliers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Bonniaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Beltramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Campagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Magy-Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Chaudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.05.015_bib0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical signs and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.015_bib0170","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of antisynthetase antibody specificities on antisynthetase syndrome clinical spectrum and time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2026.05.015_bib0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA synthetase autoantibodies have worse survival than Jo-1-positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0180","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02533-2024","article-title":"ERS\/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease","volume":"67","author":"Antoniou","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.015_bib0325","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf469","article-title":"Risk prediction model for relapse of anti-synthetase syndrome-associated interstitial lung disease in Japanese multicentre MYKO cohort study","volume":"65","author":"Matsuda","year":"2026","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arbres.2026.05.015_bib0330","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/art.43429","article-title":"Relapse rate after glucocorticoid-free remission in patients with idiopathic inflammatory myopathies and validation of the International Myositis Assessment and Clinical Studies Group criteria for complete clinical response and worsening","volume":"78","author":"Tsuji","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.015_bib0195","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomized, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.015_bib0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomized, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.015_bib0205","unstructured":"Zanframundo G, Faghihi Kashani S, Yoshida A, Dourado E, Bauer Ventura I, Rivero Gallegos D, et al. The classification criteria for anti-synthetase syndrome (CLASS) project [abstract]. Arthritis Rheumatol 2024;76(Suppl. 9). Available from: https:\/\/acrabstracts.org\/abstract\/the-classification-criteria-for-anti-synthetase-syndrome-class-project\/ [accessed 12 Jun 2026]"},{"key":"10.1016\/j.arbres.2026.05.015_bib0210","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0215","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0220","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren syndrome: a consensus and data-driven methodology involving 3 international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.015_bib0225","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0230","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1164\/rccm.202205-0963OC","article-title":"A race-neutral approach to the interpretation of lung function measurements","volume":"207","author":"Bowerman","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.015_bib0235","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard-2023-225284","article-title":"Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0240","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: an international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.015_bib0245","doi-asserted-by":"crossref","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.015_bib0250","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1002\/mus.880141111","article-title":"Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barr\u00e9 syndrome","volume":"14","author":"Kleyweg","year":"1991","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.arbres.2026.05.015_bib0255","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.sapharm.2016.11.011","article-title":"Latent class analysis: an example for reporting results","volume":"13","author":"Schreiber","year":"2017","journal-title":"Res Social Adm Pharm"},{"key":"10.1016\/j.arbres.2026.05.015_bib0260","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/10705511.2016.1247646","article-title":"The GRoLTS checklist: guidelines for reporting on latent trajectory studies","volume":"24","author":"van de Schoot","year":"2017","journal-title":"Struct Equ Modeling"},{"key":"10.1016\/j.arbres.2026.05.015_bib0265","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.015_bib0270","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fmed.2020.00363","article-title":"Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: a series of 474 patients","volume":"7","author":"Li","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.arbres.2026.05.015_bib0275","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.semarthrit.2016.03.011","article-title":"Clinical signs and long-term outcome of anti-Jo-1 antisynthetase syndrome in a large cohort of Spanish patients from the GEAS-IIM group","volume":"46","author":"Trallero-Aragu\u00e1s","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.arbres.2026.05.015_bib0280","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1573398X11666150619183527","article-title":"Outcome measures for clinical trials in interstitial lung diseases","volume":"11","author":"Lammi","year":"2015","journal-title":"Curr Respir Med Rev"},{"key":"10.1016\/j.arbres.2026.05.015_bib0285","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01205-2020","article-title":"Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype","volume":"56","author":"Graham","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.015_bib0290","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/1756-185X.14128","article-title":"Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy","volume":"24","author":"Bai","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0295","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s10067-018-4353-2","article-title":"Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease","volume":"38","author":"Cobo-Ib\u00e1\u00f1ez","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.015_bib0300","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.arbres.2026.05.015_bib0305","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2017-211868","article-title":"The EuroMyositis registry: an international collaborative tool to facilitate myositis research","volume":"77","author":"Lilleker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.arbres.2026.05.015_bib0310","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/rheumatology\/kead671","article-title":"Clinical heterogeneity and prognostic factors of antisynthetase syndrome: a multicenter retrospective cohort study","volume":"64","author":"Tang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.arbres.2026.05.015_bib0315","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.015_bib0320","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1186\/s12890-025-03962-w","article-title":"Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography: a prospective cohort study","volume":"25","author":"Qiang","year":"2025","journal-title":"BMC Pulm Med"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626002073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626002073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T08:42:44Z","timestamp":1793608964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0300289626002073"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.015","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Trajectories of Antisynthetase Syndrome-associated Interstitial Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Espa\u00f1a, S.L.U. on behalf of SEPAR.","name":"copyright","label":"Copyright"}]}}